Maternal Anemia During Pregnancy Increases Risk of Congenital Heart Defects in Newborns

Recent research highlights a significant link between anemia in early pregnancy and the likelihood of developing congenital heart defects in newborns. The study, published in BJOG: An International Journal of Obstetrics & Gynaecology, analyzed the health records of 2,776 women with children diagnosed with congenital heart disease, comparing them to 13,880 women whose children had normal heart development. Results showed that 4.4% of children with heart defects and 2.8% of those without had maternal anemia during pregnancy. After adjusting for other factors, the data indicated that anemic mothers had a 47% higher chance of giving birth to a child with a heart defect. Experts believe that this finding emphasizes the importance of monitoring and managing anemia in pregnant women, especially iron deficiency anemia, which is a common cause of maternal anemia. Addressing iron deficiency through supplementation before and during pregnancy could be a critical strategy in reducing the incidence of congenital heart conditions. These insights suggest that improving maternal nutritional health may prevent many congenital heart defects before they develop, potentially transforming prenatal care practices worldwide.
Stay Updated with Mia's Feed
Get the latest health & wellness insights delivered straight to your inbox.
Related Articles
Majority of UK Hospitals Not Screening Older Surgical Patients for Frailty
A new study reveals that nearly 75% of UK hospitals do not routinely screen older surgical patients for frailty, despite its impact on postoperative outcomes. Early assessment can lead to better care and recovery.
Experts Warn of a Complex Vaccine Landscape in 2025
Experts warn that vaccine accessibility and policy changes in 2025 could complicate COVID-19 and flu prevention efforts, impacting vulnerable populations the most.
Revolutionizing Heart Disease Treatment with AI and Omics Technologies
Emerging AI and omics technologies are revolutionizing personalized treatments for heart disease, promising targeted therapies and RNA therapeutics that could dramatically improve patient outcomes globally.
Novo Nordisk Collaborates with US Biotech Firm to Develop Innovative Obesity Medications
Novo Nordisk and Septerna have embarked on a groundbreaking partnership to develop oral medications targeting GPCRs for obesity and metabolic diseases, promising more convenient treatment options.



